Alector Q2 FY26 net loss narrows to $23 million; revenue drops to $3.3 million - ALEC News | RalliesAlector Q2 FY26 net loss narrows to $23 million; revenue drops to $3.3 million
A
ALEC• Pipeline update
- Selected AL137 as lead ABC-enabled anti-amyloid beta antibody for Alzheimer’s, targeting an IND submission in Q1 2027.
Second-quarter results
- Alector posted a Q2 net loss of USD 23 million, narrowing from USD 30.5 million a year earlier; loss per share improved to USD 0.21.
- Collaboration revenue fell 57.83% to USD 3.32 million, due to lower revenue recognized for the AL101 AD program.
- R&D expenses dropped 29.51% to USD 19.46 million; G&A expenses slid 42.69% to USD 8.25 million, both on lower personnel costs.
- Cash, cash equivalents and investments totaled USD 172.8 million at June 30; runway expected at least through 2027.
